Clinical Trials Directory

Trials / Completed

CompletedNCT02478268

Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
64 (actual)
Sponsor
Bastiaan Driehuys · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, and conventional contrast can help visualize impaired lung function and detect changes over time in patients receiving treatment as well as those who don't. 129Xe is a special type of xenon gas and when inhaled during MRI may be able to show areas of abnormal thickening of parts of the lungs. These images combined with images taken with injected contrast agents or other types of MRI may provide a better way to look at lung structure and function in patients with IPF. The ultimate goal is to predict how a particular patient might respond to a particular therapy and to observe such responses earlier than conventional tests. The investigators anticipate that the images acquired in this study will provide more specific information about lung disease than standard lung function tests. The use of 129Xe MRI is investigational. "Investigational" means that these tests have not yet been approved by the US Food and Drug Administration and are being tested in research studies like this one. In addition, standard MRI with contrast is not typically done as standard of care for monitoring progression of IPF, therefore, its use in this study is also considered investigational. Healthy volunteers are being asked to participate in this study because the investigators need to develop a database of functional images that are representative of healthy lungs.

Conditions

Interventions

TypeNameDescription
DRUGHyperpolarized 129-Xenon gasHyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
DEVICEMRIConventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.

Timeline

Start date
2015-05-01
Primary completion
2020-09-26
Completion
2020-09-26
First posted
2015-06-23
Last updated
2021-10-11

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02478268. Inclusion in this directory is not an endorsement.